Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2002-02-11
2003-03-18
Henley, III, Raymond (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
06534500
ABSTRACT:
The present invention relates to the use of cyamemazine, or the pharmaceutically acceptable salts thereof, in the treatment of abrupt benzodiazepine withdrawal by substitution of the benzodiazepine with cyamemazine.
Benzodiazepines, such as bromazepam, oxazepam, lorazepam, alprozolam, diazepam, prazepam, nordazepam, clobazam, clotiazepam or aprazolam, are the reference medicinal treatment for anxious disorders. However, the occurrence of psychological and/or physical dependency has been described in prescriptions for greater than 6 weeks (KG. POWER et al., Br. Med. J., 290, 1246 (1985)). The frequency of occurrence of the withdrawal syndrome after benzodiazepine has been stopped varies depending on the criteria chosen, but is generally of the order of 40% (R. NOYES et al., J. Clin. Psychiatry, 49, 382 (1988)).
It is therefore recommended, firstly, to limit the prescription of benzodiazepines to 3 months, renewable in certain cases of severe anxiety, and, secondly, to stop the treatment gradually. However, even when the treatment is stopped gradually, the occurrence of a withdrawal symptom may be noted, which is responsible for the benzodiazepine treatment being recommenced (E. SCHWEIZER et al., Arch. Gen. Psychiatry, 47, 908 (1990)).
Cyamemazine (TERCIAN
(R)
) is a sedative neuroleptic which, at low dose, is well tolerated. It is a treatment for anxiety which is indicated when the usual therapeutics are ineffective or in cases of neurotic or psychotic anxieties. It is also known for its action on the decrease of alcohol uptake in rats (N. NAASILA et al., Psychopharmacology, 140, 421 (1998)).
Non-benzodiazepine anxiolytics, such as buspirone, have been tested in benzodiazepine withdrawal, but have not shown any significant effect on the withdrawal syndrome (LADER et al., Journal of Clinical Psychopharmacology, 7, 1 (1987); SCHWEIZER et al., Acta Psychiatr Scandinavia, 98, sup 393 (1998)).
It has now been found that cyamemazine makes it possible to treat the symptoms, and in particular the anxiety rebound and withdrawal syndrome, occurring when benzodiazepine treatment is stopped, and thus to avoid the taking of benzodiazepines being recommenced and the treatment being perpetuated. This effect is always noted 6 months after treatment.
During a clinical trial, 2 strategies for stopping benzodiazepines were compared: either gradual withdrawal with a benzodiazepine (bromazepam) or abrupt withdrawal and substitution with cyamemazine.
The cyamemazine was studied in 168 patients, 18 to 65 years old, who had been treated with benzodiazepines (bromazepam, oxazepam, lorazepam or alprazolam) for 3 months or more, at a dose greater than or equal to 5 mg diazepam equivalent and less than 20 mg diazepam equivalent for at least 15 days, and who exhibited a score on the HAMILTON anxiety scale (Br. J. Med. Psychol., 32, 50 (1959)) of less than 18 and required benzodiazepine withdrawal. Diazepam equivalence table:
PRODUCTS
DOSE (mg)
diazepam
10
alprazolam
1
bromazepam
6
lorazepam
2.5
oxazepam
50
This is a randomized double-blind treatment which occurs over 3 periods:
1—Substitution period
The benzodiazepine is replaced either with cyamemazine or with bromazepam.
The dose is set according to the prior benzodiazepine treatment:
it is 4 gelatin capsules, taken as 2 or 3 doses a day, containing a dose of 12.5 mg of cyamemazine or 1.5 mg of bromazepam, when the prior dose of benzodiazepine is equal to or greater than 10 mg diazepam equivalents and less than 20 mg diazepam equivalent,
it is 2 gelatin capsules, taken as 2 doses a day, containing a dose of 12.5 mg of cyamemazine or 1.5 mg of bromazepam when the prior dose of benzodiazepine is equal to or greater than 5 mg diazepam equivalent and less than 10 mg diazepam equivalent.
2—Dose reduction period
The dose is either 1 or 2 gelatin capsules at 12.5 mg of cyamemazine or at 1.5 mg of bromazepam a day for 14 days, or 1 or 2 gelatin capsules at 12.5 mg of cyamemazine or at 1.5 mg of bromazepam a day for 11 days, and then 3 days of placebo.
3—Stopping period
1 or 2 gelatin capsules of placebo a day for 14 days.
The results are determined for each patient according to the following criteria:
HAMILTON anxiety scale (HARS)
ZUNG anxiety self-assessment (Official Journal of the Academy of Psychosomatic Medicine, Vol XII, No. 6 (1971))
RICKELS withdrawal scale (Arch. Gen. Psychiatry, Vol 47 (1990))
The results obtained in each of these tests make it possible to deduce that there is no significant difference between the cyamemazine treatment group and the bromazepam treatment group, concerning the maximum amplitude of the anxiety rebound (HARS scale and ZUNG anxiety scale) and the percentage of patients exhibiting an anxiety rebound. The RICKELS withdrawal scale also shows no significant difference between the 2 treatment groups concerning the frequency of occurrence of a withdrawal syndrome. However, after 6 weeks of study, the treatment is successful in a greater number of patients from the cyamemazine group (95%) than patients from the bromazepam group (85%). Moreover, after a considerable period of time (6 months) the withdrawal is still a success in 90% of the patients on cyamemazine versus 75% on bromazepam.
These results demonstrate that, when it is necessary to stop a chronic benzodiazepine treatment, cyamemazine may be used through abrupt substitution for the benzodiazepine without any consequences linked to the occurrence of an anxiety rebound or of a withdrawal syndrome. Moreover, the substitution with cyamemazine for 6 weeks is followed by a better withdrawal success rate after a considerable period of time (6 months).
The cyamemazine can be prepared according to American Patent 2877224.
As pharmaceutically acceptable salts of cyamemazine, mention may be made in particular of the addition salts with inorganic acids such as hydrochloride, sulphate, nitrate or phosphate, or with organic acids such as acetate, propionate, succinate, oxalate, benzoate, fumarate, maleate, methane-sulphonate, isethionate, theophillineacetate, salicylate, phenolphthalinate or methylenebis-&bgr;-oxy-napthoate, or substitution derivatives of these derivatives.
The medicinal products consist of at least cyamemazine in free form or in the form of an addition salt with a pharmaceutically acceptable acid, in the pure state or in the form of a composition in which it is combined with any other pharmaceutically compatible product, which may be inert or physiologically active. The medicinal products according to the invention may be used orally, parenterally, rectally or topically.
As solid compositions for oral administration, use may be made of tablets, pills, powders (gelatin capsules, cachets) or granules. In these compositions, the active principle according to the invention is mixed with one or more inert diluents, such as starch, cellulose, sucrose, lactose or silica, under a stream of argon. These compositions may also comprise substances other than the diluents, for example one or more lubricants such as magnesium stearate or talc, a dye, a coating (dragees) or a varnish.
As liquid compositions for oral administration, use may be made of pharmaceutically acceptable solutions, suspensions, emulsions, syrups and elixirs containing inert diluents such as water, ethanol, glycerol, plant oils or liquid paraffin. These compositions may comprise substances other than the diluents, for example wetting products, sweeteners, thickeners, flavouring products or stabilizers.
The sterile compositions for parenteral administration may preferably be aqueous or nonaqueous solutions, suspensions or emulsions. Solvents or vehicles which may be used include water, propylene glycol, a polyethylene glycol, plant oils, in particular olive oil, injectable organic esters, for example ethyl oleate, or other suitable organic solvents. These compositions may also contain adjuvants, in particular wetting agents, isotonic agents, emulsifiers, dispersants and stabilizers. The sterilization may be carried out in several ways, for example by aseptic filtration, by incorporating sterilizing agents into
Aventis Pharma S.A.
Bolcsak James W.
Henley III Raymond
LandOfFree
Use of cyamemazine in the treatment of abrupt... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of cyamemazine in the treatment of abrupt..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of cyamemazine in the treatment of abrupt... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3079920